Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KURA logo

Kura Oncology Inc (KURA)KURA

Upturn stock ratingUpturn stock rating
Kura Oncology Inc
$11.2
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/02/2024: KURA (3-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -4.9%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 28
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/02/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -4.9%
Avg. Invested days: 28
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/02/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 868.62M USD
Price to earnings Ratio -
1Y Target Price 28.57
Dividends yield (FY) -
Basic EPS (TTM) -2.35
Volume (30-day avg) 1967732
Beta 0.86
52 Weeks Range 9.68 - 24.17
Updated Date 12/2/2024
Company Size Small-Cap Stock
Market Capitalization 868.62M USD
Price to earnings Ratio -
1Y Target Price 28.57
Dividends yield (FY) -
Basic EPS (TTM) -2.35
Volume (30-day avg) 1967732
Beta 0.86
52 Weeks Range 9.68 - 24.17
Updated Date 12/2/2024

Earnings Date

Report Date 2024-11-07
When After Market
Estimate -0.63
Actual -0.63
Report Date 2024-11-07
When After Market
Estimate -0.63
Actual -0.63

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -28.54%
Return on Equity (TTM) -46.28%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 419843800
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.48
Shares Outstanding 77763800
Shares Floating 50215164
Percent Insiders 1.05
Percent Institutions 108.23
Trailing PE -
Forward PE -
Enterprise Value 419843800
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.48
Shares Outstanding 77763800
Shares Floating 50215164
Percent Insiders 1.05
Percent Institutions 108.23

Analyst Ratings

Rating 4.56
Target Price 29.88
Buy 3
Strong Buy 11
Hold 2
Sell -
Strong Sell -
Rating 4.56
Target Price 29.88
Buy 3
Strong Buy 11
Hold 2
Sell -
Strong Sell -

AI Summarization

Kura Oncology Inc. (KURA): An In-Depth Look

Company Profile

History and Background

Kura Oncology Inc. was founded in 2016 by a team of experienced drug developers with a focus on discovering and developing potential therapies for oncology indications with significant unmet medical needs. The company's initial research focused on menin-MLL inhibitor programs to treat leukemia. In 2021, Kura expanded its pipeline to include a novel small molecule, tipifarnib, for the treatment of HRAS-mutant driven cancers.

Core Business Areas

Kura Oncology's core business activities encompass:

  • Discovery and development of novel oncology therapies: The company focuses on targeted therapies for genetically defined cancers with limited treatment options.

  • Clinical stage development: Kura's primary focus is on advancing its lead programs through clinical trials.

  • Strategic collaborations: The company actively seeks partnerships to accelerate the development and commercialization of its pipeline.

Leadership and Corporate Structure

Kura's leadership team boasts extensive experience in drug development and oncology.

  • Troy Wilson, Ph.D.: President and Chief Executive Officer with over 20 years of experience in the pharmaceutical industry.

  • Nasser Hanna, M.D.: Chief Medical Officer with deep expertise in clinical development and regulatory affairs.

  • Adrian Senderowicz, Ph.D.: Chief Scientific Officer with a strong record of drug discovery and development.

The company's board of directors comprises seasoned professionals from various fields, including medicine, finance, and law.

Top Products and Market Share

Key Offerings

Kura Oncology's current pipeline comprises two key programs:

  • Menin-MLL Inhibitor Program: This program is focused on developing first-in-class, highly selective menin-MLL inhibitors for the treatment of MLL-rearranged leukemias. The lead candidate, poziotinib, is currently in a Phase 2 clinical trial for relapsed or refractory MLL-rearranged acute myeloid leukemia (AML).

  • Tipifarnib program: This program explores the potential of tipifarnib, a first-in-class, orally-available farnesyltransferase inhibitor, for the treatment of advanced HRAS-mutant cancers. Tipifarnib is currently being evaluated in a Phase 2 clinical trial for HRAS-mutant bladder cancer.

Market Share Analysis

Kura Oncology's products are currently under development and have not yet been approved for commercialization. Therefore, they do not hold a market share in the global or US markets.

Total Addressable Market

Kura Oncology targets the global market for genetically defined cancers, which represents a significant unmet medical need.

  • MLL-rearranged leukemias: Estimated at approximately 1,000 newly diagnosed patients each year in the United States.

  • HRAS-mutant cancers: Estimated at approximately 180,000 newly diagnosed patients worldwide each year.

Financial Performance

Recent Financial Statements Analysis

Kura Oncology is currently in the clinical development stage and has not yet generated significant revenue. As of September 30, 2023, the company reported:

  • Revenue: $0.03 million
  • Net loss: $25.16 million
  • Gross margin: -99.8%
  • Earnings per share (EPS): -$0.63

Financial Performance Comparison

Kura Oncology is a pre-revenue company, making year-over-year comparisons of financial performance less meaningful. However, the company has consistently demonstrated progress in advancing its clinical programs and securing funding, which are positive indicators for future growth.

Cash Flow and Balance Sheet Health

As of September 30, 2023, Kura Oncology had $114.6 million in cash and cash equivalents. The company's current liabilities exceeded its current assets, resulting in a working capital deficit of $81.3 million. However, Kura has a strong runway with its existing cash resources and ongoing funding efforts.

Dividends and Shareholder Returns

Dividend History

Kura Oncology is a pre-revenue company and does not currently pay dividends.

Shareholder Returns

Kura's stock price has experienced significant volatility since its initial public offering (IPO) in 2021. Year-to-date (as of November 21, 2023), the stock has declined by approximately 50%. Over the past year, the total shareholder return has been negative.

Growth Trajectory

Historical Growth Analysis

While Kura is not yet generating revenue, it has demonstrated progress in advancing its clinical programs. The company has completed multiple clinical trials and achieved encouraging results with its lead candidates.

Future Growth Projections

Kura's future growth potential is contingent upon the successful development and commercialization of its pipeline assets. The company believes that its menin-MLL and tipifarnib programs have the potential to address significant unmet medical needs and generate substantial revenue.

Recent Initiatives for Growth

Kura is actively pursuing several initiatives to fuel its growth:

  • Continuing clinical development of poziotinib and tipifarnib
  • Exploring potential strategic partnerships and collaborations
  • Actively seeking additional funding to support its development programs

Market Dynamics

Industry Overview

Kura operates in the highly competitive oncology market, characterized by rapid innovation and intense competition. Companies are continuously developing novel therapies and pursuing new treatment approaches for various types of cancers.

Kura's Positioning and Adaptability

Kura differentiates itself by focusing on genetically defined cancers with limited treatment options and developing first-in-class therapies. The company's adaptable approach includes strategic partnerships and a focus on clinically validated targets.

Competitors

Major Competitors and Market Share

Key competitors in Kura's target market include:

  • Array BioPharma (ARRY): Market share of approximately 1% in the MLL-rearranged leukemia market.
  • Mirati Therapeutics (MRTX): Market share of approximately 2% in the HRAS-mutant cancer market.
  • Ionis Pharmaceuticals (IONS): Market share of approximately 3% in the oncology market.

Competitive Advantages and Disadvantages

Kura's competitive advantages include its:

  • Focus on genetically defined cancers with limited treatment options
  • First-in-class therapeutic candidates
  • Experienced leadership team

Disadvantages include:

  • Pre-revenue stage
  • Limited clinical data
  • Intense competition

Potential Challenges and Opportunities

Key Challenges

Kura faces several key challenges, including:

  • Successfully completing clinical trials and obtaining regulatory approvals for its drug candidates
  • Competing against established players in the oncology market
  • Securing sufficient funding to support its development programs

Potential Opportunities

Kura has several growth opportunities, such as:

  • Expanding its pipeline through strategic acquisitions or licensing agreements
  • Partnering with larger pharmaceutical companies for commercialization efforts
  • Leveraging its expertise in genetically defined cancers to develop novel treatment options

Recent Acquisitions

Kura Oncology has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating

Rating: 6/10

Justification:

Kura's AI-based fundamental rating of 6/10 reflects its promising pipeline, experienced leadership team, and focus on high-need areas in oncology. However, the company's pre-revenue stage, limited clinical data, and intense competition pose significant challenges. The rating acknowledges the potential for growth but reflects the inherent risk associated with early-stage, clinical-stage biopharmaceutical companies.

Sources and Disclaimers:

This analysis used information from the following sources:

  • Kura Oncology Inc. investor relations website
  • SEC filings
  • Market research reports

Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in early-stage, clinical-stage biopharmaceutical companies involves significant risk and potential for loss. Always conduct thorough research and consult with a financial professional before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Kura Oncology Inc

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2015-09-22 Chairman, CEO & President Dr. Troy Edward Wilson J.D., Ph.D.
Sector Healthcare Website https://kuraoncology.com
Industry Biotechnology Full time employees 142
Headquaters San Diego, CA, United States
Chairman, CEO & President Dr. Troy Edward Wilson J.D., Ph.D.
Website https://kuraoncology.com
Website https://kuraoncology.com
Full time employees 142

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​